The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Authors
Keywords
Multiple sclerosis, Therapeutic drug monitoring, Selection for treatment, Re-treatment, Treatment effectiveness
Journal
JOURNAL OF NEUROLOGY
Volume 264, Issue 12, Pages 2351-2374
Publisher
Springer Nature
Online
2017-09-07
DOI
10.1007/s00415-017-8594-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Classifying PML risk with disease modifying therapies
- (2017) Joseph R. Berger Multiple Sclerosis and Related Disorders
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials
- (2016) Lei Diao et al. CLINICAL PHARMACOKINETICS
- Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
- (2016) Harold L Atkins et al. LANCET
- Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications
- (2016) Giordani Rodrigues Dos Passos et al. MEDIATORS OF INFLAMMATION
- The challenge of comorbidity in clinical trials for multiple sclerosis
- (2016) Ruth Ann Marrie et al. NEUROLOGY
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- (2016) Anthony L. Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
- (2016) Horst Penkert et al. JAMA Neurology
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- (2016) Giancarlo Comi et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Brain health: time matters in multiple sclerosis
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Defining high, medium and low impact prognostic factors for developing multiple sclerosis
- (2015) Mar Tintore et al. BRAIN
- Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation
- (2015) Benjamin Berger et al. JOURNAL OF NEUROIMMUNOLOGY
- Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
- (2015) Jeroen Van Schependom et al. Multiple Sclerosis Journal
- Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis
- (2015) Gaspard Gerschenfeld et al. Multiple Sclerosis Journal
- Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial
- (2015) G. L. Mancardi et al. NEUROLOGY
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
- (2015) L. Kappos et al. NEUROLOGY
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
- (2015) Jens Ingwersen et al. Neurotherapeutics
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)
- (2015) Richard A. Nash et al. JAMA Neurology
- Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
- (2015) Dalia L. Rotstein et al. JAMA Neurology
- Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
- (2015) Jeroen Van Schependom et al. Multiple Sclerosis Journal
- Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis
- (2015) Gaspard Gerschenfeld et al. Multiple Sclerosis Journal
- The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS)
- (2015) Sura Alwan et al. Multiple Sclerosis and Related Disorders
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Optimizing therapy early in multiple sclerosis: An evidence-based view
- (2015) Tjalf Ziemssen et al. Multiple Sclerosis and Related Disorders
- The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
- (2015) Per Soelberg Sorensen et al. Therapeutic Advances in Neurological Disorders
- Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
- (2015) Roberto Bomprezzi Therapeutic Advances in Neurological Disorders
- Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
- (2015) Alberto Gajofatto et al. World Journal of Clinical Cases
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
- (2014) Mark S. Freedman et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
- (2014) Renaud A. Du Pasquier et al. CNS DRUGS
- New management algorithms in multiple sclerosis
- (2014) Per Soelberg Sorensen CURRENT OPINION IN NEUROLOGY
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- (2014) Amit Bar-Or et al. DRUGS
- In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
- (2014) David J. Huss et al. JOURNAL OF IMMUNOLOGY
- Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
- (2014) Michael Kaufman et al. JOURNAL OF NEUROLOGY
- Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
- (2014) Cecilie Jacobsen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
- (2014) Michael Kaufman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
- (2014) Gavin Giovannoni et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes
- (2014) G. Giovannoni et al. NEUROLOGY
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
- (2014) Marinella Clerico et al. JAMA Neurology
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
- (2014) Martin Stangel et al. Therapeutic Advances in Neurological Disorders
- Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
- (2014) Vissia Viglietta et al. Annals of Clinical and Translational Neurology
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
- (2013) Claudio Gobbi et al. BMC Neurology
- Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
- (2013) Gilles Edan et al. CNS DRUGS
- Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
- (2013) Gilbert H. Daniels et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
- (2013) Gavin Giovannoni et al. JOURNAL OF NEUROLOGY
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- (2013) Veronica Popescu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study
- (2013) L Lavorgna et al. Multiple Sclerosis Journal
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
- (2013) G Francis et al. Multiple Sclerosis Journal
- Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
- (2013) Heinz Wiendl et al. Nature Reviews Neurology
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
- (2013) A. Bar-Or et al. NEUROLOGY
- The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
- (2013) Ron Milo Therapeutic Advances in Neurological Disorders
- New Disease-Modifying Therapies and New Challenges for MS
- (2012) Vijayshree Yadav et al. Current Neurology and Neuroscience Reports
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Epigenetic changes in patients with multiple sclerosis
- (2012) Marcus W. Koch et al. Nature Reviews Neurology
- Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
- (2012) M. D. Cossburn et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Daclizumab Therapy for Multiple Sclerosis
- (2012) Bibiana Bielekova Neurotherapeutics
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis
- (2012) J. S. A. Perry et al. Science Translational Medicine
- Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
- (2012) Douglas S Goodin et al. BMJ Open
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
- (2011) Xiao Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients
- (2011) T. A. Johnson et al. JOURNAL OF IMMUNOLOGY
- Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
- (2011) Grant A Hill-Cawthorne et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Natalizumab and HSV meningitis
- (2011) Erica Seiguer Shenoy et al. JOURNAL OF NEUROVIROLOGY
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- (2011) A. Kerbrat et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
- (2011) Stephen Sawcer et al. NATURE
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glatiramer Acetate Treatment Directly Targets CD11b+ Ly6G− Monocytes and Enhances the Suppression of Autoreactive T cells in Experimental Autoimmune Encephalomyelitis
- (2011) A. Toker et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
- (2011) Bernard Uitdehaag et al. Therapeutic Advances in Neurological Disorders
- Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?
- (2010) Amy E. Lovett-Racke et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
- (2010) Antonio Scalfari et al. BRAIN
- Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis
- (2010) Stephanie C. Steinberg et al. CLINICAL DRUG INVESTIGATION
- Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
- (2010) Trina A. Johnson et al. CLINICAL IMMUNOLOGY
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
- (2010) V. Devonshire et al. EUROPEAN JOURNAL OF NEUROLOGY
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
- (2010) J. F. Martin et al. JOURNAL OF IMMUNOLOGY
- Neurofilament light as a prognostic marker in multiple sclerosis
- (2010) Jonatan Salzer et al. Multiple Sclerosis Journal
- Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM
- (2010) Patrizia Sola et al. Multiple Sclerosis Journal
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis
- (2010) Robert C Axtell et al. NATURE MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- New approaches in the management of multiple sclerosis
- (2010) Douglas Allington Drug Design Development and Therapy
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command
- (2009) Mark S. Freedman et al. CURRENT MEDICAL RESEARCH AND OPINION
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Measures in the first year of therapy predict the response to interferon β in MS
- (2009) J Río et al. Multiple Sclerosis Journal
- Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
- (2009) Luciano Rinaldi et al. NEUROLOGICAL SCIENCES
- Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
- (2009) E. M. Mowry et al. NEUROLOGY
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- (2009) B. O. Khatri et al. NEUROLOGY
- Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
- (2008) D. L. Arnold et al. JOURNAL OF NEUROLOGY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
- (2008) T Vollmer et al. Multiple Sclerosis Journal
- Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
- (2008) Christine Lebrun et al. Multiple Sclerosis Journal
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More